



1624
IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Serge Beaudoin, et al.

Atty. Docket

Confirmation No. 9077

No.: 4208.00034

Customer No. 22907

Application No.: 10/004,867

Group Art Unit: 1624

Filed: December 7, 2001

Examiner: Truong, T.N.

For: POTASSIUM CHANNEL INHIBITORS

AMENDMENT C - AFTER FINAL

*Fee Purpose
only*

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This amendment is filed under Rule 1.116 in response to the final Office Action dated May 19, 2004. Applicants hereby petition for a one (1) month extension in the response period and authorize the Commissioner to charge our Deposit Account No. 19-0733 for the extension fee.

Amendments to the claims are reflected in the listing of claims that begins on page 2 of this paper.

Remarks begin on page 8 of this paper.

09/15/2004 GTRAMMEL 00000004 190733 10004867


01 FC:1251 110.00 DA

Claim 22 is rejected under 35 U.S.C. 112, first paragraph, as failing to provide both an adequate written description and as lacking enablement for cell proliferative disorder. While applicants, for reasons presented in the prior Amendment B believe that this rejection is inappropriate, in the interest of facilitating prosecution, applicants have cancelled claim 22. Accordingly, this rejection now should be withdrawn in view of the cancellation of claim 22.

On the basis of the foregoing, prompt reconsideration of claims 1-21 in the subject application is respectfully requested.

Respectfully submitted,

BANNER & WITCOFF, LTD.

A large, stylized handwritten signature in black ink, appearing to read 'JMS', is written over a horizontal line.

By:

Joseph M. Skerpon
Registration No. 29,864

Date: September 13, 2004

1001 G Street, N.W.
Washington, D.C. 20001-4597
(202) 824-3000
JMS/bao